Digital Tomosynthesis Mammography Shows Promise in Breast Cancer Screening
A randomized phase III trial suggests that digital tomosynthesis mammography may be superior to digital mammography for breast cancer screening.
Phase III
ECOG-ACRIN Cancer Research Group
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The trial results indicating that digital tomosynthesis mammography may outperform traditional digital mammography could lead to significant changes in breast cancer screening protocols. This shift may affect product development strategies and partnerships for companies involved in breast cancer diagnostics.
Recommended action
Humanexa recommends Monitor.
Analysis
Follow-up on trial results and potential adoption of tomosynthesis in clinical guidelines.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.